Healthcare / Drug Manufacturers - Specialty & GenericCanadian Sec
$0.23
+0.00 (+2.27%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-7.3M · quality 66.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$63M
P/E
N/A
•EV/EBITDA
N/A
•ROE
213.2%
↑Gross Margin
30.1%
↓Debt/Equity
-1.52
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+8.8%
FCF CAGR
—
FCF margin
-4.3%
FCF / Net income
0.08x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $34.8M · net income $-17.6M · FCF $-1.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $34.8M | $34.8M | $28.5M | $30.6M | $27.0M |
| Net Income | $-17.6M | $-17.6M | $-24.6M | $-35.0M | $-28.9M |
| EBITDA | $-10.4M | $-10.4M | $-14.3M | $-33.4M | $-18.9M |
| EPS | -0.10 | -0.10 | -0.17 | -0.30 | -0.40 |
| Gross Margin | 30.1% | 30.1% | 27.0% | 32.7% | 35.4% |
| Operating Margin | -15.1% | -15.1% | -18.7% | -20.4% | -60.7% |
| Net Margin | -50.7% | -50.7% | -86.4% | -114.2% | -107.1% |
| Balance Sheet | |||||
| Debt/Equity | -1.52 | -1.52 | -1.86 | -7.27 | 0.46 |
| Current Ratio | 1.75 | 1.75 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-1.5M | $-1.5M | $-7.3M | $-7.4M | $-6.4M |
| Returns | |||||
| ROE | 213.2% | 213.2% | 198.0% | 1248.1% | -120.8% |
| Valuation | |||||
| P/B | — | — | — | — | 2.14 |
| Growth & Yield | |||||
| Revenue Growth | 22.1% | 22.1% | -6.9% | 13.4% | — |
| EPS Growth | 41.2% | 41.2% | 43.3% | 25.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-6.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.17 → -0.10
Residual
-6.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.